Diagnosis of Alzheimer’s disease utilizing amyloid and tau as fluid biomarkers

Jinny Claire Lee, Soo Jung Kim, Seungpyo Hong, YoungSoo Kim

Research output: Contribution to journalReview article

Abstract

Current technological advancements in clinical and research settings have permitted a more intensive and comprehensive understanding of Alzheimer’s disease (AD). This development in knowledge regarding AD pathogenesis has been implemented to produce disease-modifying drugs. The potential for accessible and effective therapeutic methods has generated a need for detecting this neurodegenerative disorder during early stages of progression because such remedial effects are more profound when implemented during the initial, prolonged prodromal stages of pathogenesis. The aggregation of amyloid-β (Aβ) and tau isoforms are characteristic of AD; thus, they are considered core candidate biomarkers. However, research attempting to establish the reliability of Aβ and tau as biomarkers has culminated in an amalgamation of contradictory results and theories regarding the biomarker concentrations necessary for an accurate diagnosis. In this review, we consider the capabilities and limitations of fluid biomarkers collected from cerebrospinal fluid, blood, and oral, ocular, and olfactory secretions as diagnostic tools for AD, along with the impact of the integration of these biomarkers in clinical settings. Furthermore, the evolution of diagnostic criteria and novel research findings are discussed. This review is a summary and reflection of the ongoing concerted efforts to establish fluid biomarkers as a diagnostic tool and implement them in diagnostic procedures.

Original languageEnglish
Article number53
JournalExperimental and Molecular Medicine
Volume51
Issue number5
DOIs
Publication statusPublished - 2019 May 1

Fingerprint

Biomarkers
Amyloid
Alzheimer Disease
Fluids
Research
Prodromal Symptoms
Cerebrospinal fluid
Neurodegenerative Diseases
Cerebrospinal Fluid
Protein Isoforms
Blood
Agglomeration
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Molecular Medicine
  • Molecular Biology
  • Clinical Biochemistry

Cite this

@article{8636f8ec0df84e25829b4617e9dba3e2,
title = "Diagnosis of Alzheimer’s disease utilizing amyloid and tau as fluid biomarkers",
abstract = "Current technological advancements in clinical and research settings have permitted a more intensive and comprehensive understanding of Alzheimer’s disease (AD). This development in knowledge regarding AD pathogenesis has been implemented to produce disease-modifying drugs. The potential for accessible and effective therapeutic methods has generated a need for detecting this neurodegenerative disorder during early stages of progression because such remedial effects are more profound when implemented during the initial, prolonged prodromal stages of pathogenesis. The aggregation of amyloid-β (Aβ) and tau isoforms are characteristic of AD; thus, they are considered core candidate biomarkers. However, research attempting to establish the reliability of Aβ and tau as biomarkers has culminated in an amalgamation of contradictory results and theories regarding the biomarker concentrations necessary for an accurate diagnosis. In this review, we consider the capabilities and limitations of fluid biomarkers collected from cerebrospinal fluid, blood, and oral, ocular, and olfactory secretions as diagnostic tools for AD, along with the impact of the integration of these biomarkers in clinical settings. Furthermore, the evolution of diagnostic criteria and novel research findings are discussed. This review is a summary and reflection of the ongoing concerted efforts to establish fluid biomarkers as a diagnostic tool and implement them in diagnostic procedures.",
author = "Lee, {Jinny Claire} and Kim, {Soo Jung} and Seungpyo Hong and YoungSoo Kim",
year = "2019",
month = "5",
day = "1",
doi = "10.1038/s12276-019-0250-2",
language = "English",
volume = "51",
journal = "Experimental and Molecular Medicine",
issn = "1226-3613",
publisher = "Korean Society of Med. Biochemistry and Mol. Biology",
number = "5",

}

Diagnosis of Alzheimer’s disease utilizing amyloid and tau as fluid biomarkers. / Lee, Jinny Claire; Kim, Soo Jung; Hong, Seungpyo; Kim, YoungSoo.

In: Experimental and Molecular Medicine, Vol. 51, No. 5, 53, 01.05.2019.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Diagnosis of Alzheimer’s disease utilizing amyloid and tau as fluid biomarkers

AU - Lee, Jinny Claire

AU - Kim, Soo Jung

AU - Hong, Seungpyo

AU - Kim, YoungSoo

PY - 2019/5/1

Y1 - 2019/5/1

N2 - Current technological advancements in clinical and research settings have permitted a more intensive and comprehensive understanding of Alzheimer’s disease (AD). This development in knowledge regarding AD pathogenesis has been implemented to produce disease-modifying drugs. The potential for accessible and effective therapeutic methods has generated a need for detecting this neurodegenerative disorder during early stages of progression because such remedial effects are more profound when implemented during the initial, prolonged prodromal stages of pathogenesis. The aggregation of amyloid-β (Aβ) and tau isoforms are characteristic of AD; thus, they are considered core candidate biomarkers. However, research attempting to establish the reliability of Aβ and tau as biomarkers has culminated in an amalgamation of contradictory results and theories regarding the biomarker concentrations necessary for an accurate diagnosis. In this review, we consider the capabilities and limitations of fluid biomarkers collected from cerebrospinal fluid, blood, and oral, ocular, and olfactory secretions as diagnostic tools for AD, along with the impact of the integration of these biomarkers in clinical settings. Furthermore, the evolution of diagnostic criteria and novel research findings are discussed. This review is a summary and reflection of the ongoing concerted efforts to establish fluid biomarkers as a diagnostic tool and implement them in diagnostic procedures.

AB - Current technological advancements in clinical and research settings have permitted a more intensive and comprehensive understanding of Alzheimer’s disease (AD). This development in knowledge regarding AD pathogenesis has been implemented to produce disease-modifying drugs. The potential for accessible and effective therapeutic methods has generated a need for detecting this neurodegenerative disorder during early stages of progression because such remedial effects are more profound when implemented during the initial, prolonged prodromal stages of pathogenesis. The aggregation of amyloid-β (Aβ) and tau isoforms are characteristic of AD; thus, they are considered core candidate biomarkers. However, research attempting to establish the reliability of Aβ and tau as biomarkers has culminated in an amalgamation of contradictory results and theories regarding the biomarker concentrations necessary for an accurate diagnosis. In this review, we consider the capabilities and limitations of fluid biomarkers collected from cerebrospinal fluid, blood, and oral, ocular, and olfactory secretions as diagnostic tools for AD, along with the impact of the integration of these biomarkers in clinical settings. Furthermore, the evolution of diagnostic criteria and novel research findings are discussed. This review is a summary and reflection of the ongoing concerted efforts to establish fluid biomarkers as a diagnostic tool and implement them in diagnostic procedures.

UR - http://www.scopus.com/inward/record.url?scp=85065568938&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065568938&partnerID=8YFLogxK

U2 - 10.1038/s12276-019-0250-2

DO - 10.1038/s12276-019-0250-2

M3 - Review article

C2 - 31073121

AN - SCOPUS:85065568938

VL - 51

JO - Experimental and Molecular Medicine

JF - Experimental and Molecular Medicine

SN - 1226-3613

IS - 5

M1 - 53

ER -